Desvenlafaxine

• CAT Number: A000978
• CAS Number: 93413-62-8
• Molecular Formula: C16H25NO2
• Molecular Weight: 263.4
• Purity: ≥95%
• Synonyms: O-Desmethylvenlafaxine; 93413-62-8; 4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol; Pristiq; 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
• Target: 5-HT Receptor
• Solubility: >11mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
• InChI: InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
• InChIKey: KYYIDSXMWOZKMP-UHFFFAOYSA-N
• SMILES: CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O

Desvenlafaxine (CAS 93413-62-8) (brand name: Pristiq, Desfax), also known as O-desmethylvenlafaxine, is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class developed and marketed by Wyeth (now part of Pfizer). Desvenlafaxine is a synthetic form of the major active metabolite of venlafaxine (sold under the brand names Effexor and Efexor). It is being targeted as the first non-hormonal based treatment for menopause. Desvenlafaxine is a synthetic phenethylamine bicyclic derivative with antidepressant activity. Desvenlafaxine is a selective reuptake inhibitor of serotonin and norepinephrine due to its high binding affinities to the pre-synaptic serotonin and norepinephrine transporters. By blocking both transporters, this agent prolongs neurotransmitter activities of both serotonin and norepinephrine, thereby alleviating depressive state.

Overview of Clinical Research

Desvenlafaxine is an adrenergic uptake inhibitor and a serotonin uptake inhibitor. Mochida Pharmaceutical and Pfizer initiated a phase III trial in Major depressive disorders in Japan (PO) before May 2020 (NCT04345471).

Reference

1: Nichols AI, Liao S, Abbas R. Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations. Clin Pharmacol Drug Dev. 2017 Dec 11. doi: 10.1002/cpdd.419. [Epub ahead of print] PubMed PMID: 29228473.
2: Weihs KL, Murphy W, Abbas R, Chiles D, England RD, Ramaker S, Wajsbrot DB. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder. J Child Adolesc Psychopharmacol. 2017 Nov 30. doi: 10.1089/cap.2017.0100. [Epub ahead of print] PubMed PMID: 29189044.
3: Atkinson S, Lubaczewski S, Ramaker S, England RD, Wajsbrot DB, Abbas R, Findling RL. Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder. J Child Adolesc Psychopharmacol. 2017 Nov 29. doi: 10.1089/cap.2017.0099. [Epub ahead of print] PubMed PMID: 29185786.
4: Farley TM, Anderson EN, Feller JN. False-positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use. BMJ Case Rep. 2017 Nov 23;2017. pii: bcr-2017-222106. doi: 10.1136/bcr-2017-222106. PubMed PMID: 29170178.
5: Gurunathan U. Takotsubo Cardiomyopathy and Intraoperative Cardiac Arrest: Is Desvenlafaxine a Contributing Factor? J Cardiothorac Vasc Anesth. 2017 Aug 19. pii: S1053-0770(17)30713-9. doi: 10.1053/j.jvca.2017.08.031. [Epub ahead of print] PubMed PMID: 29153932.
6: Soares CN, Zhang M, Boucher M. Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine. CNS Spectr. 2017 Nov 15:1-11. doi: 10.1017/S1092852917000633. [Epub ahead of print] PubMed PMID: 29140227.
7: Tong GF, Qin N, Sun LW. Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. Saudi Pharm J. 2017 Sep;25(6):844-851. doi: 10.1016/j.jsps.2016.12.003. Epub 2016 Dec 23. PubMed PMID: 28951668; PubMed Central PMCID: PMC5605887.
8: Katzman MA, Nierenberg AA, Wajsbrot DB, Meier E, Prieto R, Pappadopulos E, Mackell J, Boucher M. Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder. J Clin Psychopharmacol. 2017 Oct;37(5):555-561. doi: 10.1097/JCP.0000000000000775. PubMed PMID: 28817491; PubMed Central PMCID: PMC5596832.
9: Sarfati D, Evans VC, Tam EM, Woo C, Iverson GL, Yatham LN, Lam RW. The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol. 2017 Nov;32(6):343-349. doi: 10.1097/YIC.0000000000000192. PubMed PMID: 28763344.
10: Samy W, Elnoby A, El-Gowelli HM, Elgindy N. Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets. Saudi Pharm J. 2017 Jul;25(5):676-687. doi: 10.1016/j.jsps.2016.10.005. Epub 2016 Oct 17. PubMed PMID: 28725139; PubMed Central PMCID: PMC5506642.